| abstract |
The inventors of the present invention examined HCV replicon inhibitory activity of U18666A, and it was found that this compound has an effect of inhibiting HCV replicon RNA replication or HCV protein expression. Furthermore, the inventors of the present invention conducted a knockdown experiment of DHCR24 using siRNA, and it was revealed that HCV replicon activity and HCV protein expression were significantly inhibited in cells in which DHCR24 expression was suppressed. From the above, it was clarified that HCV infection can be treated or prevented by inhibiting the enzyme activity involved in the cholesterol biosynthesis process. |